drugset / Trial / NCT04906213

CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

NCT04906213

Phase 2 Terminated 20 enrolled Duke University
RandomizedParallel-groupTriple-blindPrevention

Summary

CREST-KT is a single-center, double-blinded, randomized trial of empagliflozin therapy in 72 kidney transplant recipients with (n=36) and without type 2 diabetes (n=36). After evenly dividing patients by type 2 diabetes diagnosis, patients will be randomized 2:1 to empagliflozin 10mg versus placebo.

Timeline

Start
2022-07-25
Primary completion
2026-01-22
Completion
2026-01-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Empagliflozin Small molecule 10 mg